U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H14N2O2.ClH
Molecular Weight 230.691
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SOLRIAMFETOL HYDROCHLORIDE

SMILES

Cl.N[C@@H](COC(N)=O)CC1=CC=CC=C1

InChI

InChIKey=KAOVAAHCFNYXNJ-SBSPUUFOSA-N
InChI=1S/C10H14N2O2.ClH/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8;/h1-5,9H,6-7,11H2,(H2,12,13);1H/t9-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H14N2O2
Molecular Weight 194.2304
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

ADX-N05, originally discovered by SK Holdings, is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). ADX-N05 (Solriamfetol, sold under the brand name Sunosi) is approved in the US and is under regulatory review in the EU to improve wakefulness in adult patients with hypersomnia associated with narcolepsy or obstructive sleep apnoea.The US FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
4.4 µM [IC50]
2.9 µM [IC50]
PubMed

PubMed

TitleDatePubMed
Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
2015 Sep
Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: A Phase 2b Study.
2016 Jul 1
New developments in the management of narcolepsy.
2017

Sample Use Guides

In Vivo Use Guide
The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75 mg and 150 mg doses, and in obstructive sleep apnea in once-daily 37.5 mg, 75 mg, and 150 mg doses.
Route of Administration: Oral
In Vitro Use Guide
Solriamfetol binds to the dopamine transporter and norepinephrine transporter with low affinity (Ki=14.2 uM and 3.7 uM, respectively), and inhibits the reuptake of dopamine and norepinephrine with low potency (IC50 =2.9 uM and 4.4 uM, respectively). Solriamfetol has no appreciable binding affinity for the serotonin transporter (Ki=81.5 uM) and does not inhibit serotonin reuptake (IC50 > 100 uM).
Substance Class Chemical
Created
by admin
on Mon Oct 21 20:11:40 UTC 2019
Edited
by admin
on Mon Oct 21 20:11:40 UTC 2019
Record UNII
K7RO88SP7A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SOLRIAMFETOL HYDROCHLORIDE
USAN  
Official Name English
ADX-N05 HYDROCHLORIDE
Code English
ADX-N-05 HYDROCHLORIDE
Code English
YKP-10A HYDROCHLORIDE
Code English
(2R)-2-AMINO-3-PHENYLPROPYL CARBAMATE, MONOHYDROCHLORIDE
Systematic Name English
BENZENEPROPANOL, .BETA.-AMINO-, 1-CARBAMATE, HYDROCHLORIDE (1:1), (.BETA.R)-
Systematic Name English
SKL-N-05 HYDROCHLORIDE
Code English
SOLRIAMFETOL HYDROCHLORIDE [WHO-DD]
Common Name English
R-228060 HYDROCHLORIDE
Code English
SOLRIAMFETOL HYDROCHLORIDE [USAN]
Common Name English
JZP-110 HYDROCHLORIDE
Code English
(R)-(+)-2-AMINO-1-CARBAMOYLOXY-3-PHENYLPROPANE HYDROCHLORIDE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 375112
Created by admin on Mon Oct 21 20:11:40 UTC 2019 , Edited by admin on Mon Oct 21 20:11:40 UTC 2019
Code System Code Type Description
MESH
C470510
Created by admin on Mon Oct 21 20:11:40 UTC 2019 , Edited by admin on Mon Oct 21 20:11:40 UTC 2019
PRIMARY
PUBCHEM
67583702
Created by admin on Mon Oct 21 20:11:40 UTC 2019 , Edited by admin on Mon Oct 21 20:11:40 UTC 2019
PRIMARY
CAS
178429-65-7
Created by admin on Mon Oct 21 20:11:40 UTC 2019 , Edited by admin on Mon Oct 21 20:11:40 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY